Latest News

Cyclomics Selected for Google for Startups Cloud Program

Cyclomics has been accepted into the Google Cloud Startup Program to support its growing computational needs for big data and AI model training.

Welcome to Marc Pagès Gallego, our ML and AI expert

Cyclomics announces announce the expansion of the team with the addition of Marc Pagès Gallego to boost ML and AI applications based on Cyclomics' technologies.

Wigard Kloosterman is our new CEO

Cyclomics announces that co-founder Wigard Kloosterman will assume the role of Chief Executive Officer. Wigard brings extensive experience from both academia and biotechnology to drive Cyclomics’ mission of advancing liquid biopsy technology.

GEDiCube and Cyclomics sign binding LOI to join forces and position themselves at the forefront of the global liquid biopsy marketplace Copy

GEDiCube intend to acquire Cyclomics, combining technologies to advance early cancer detection and recurrence monitoring using a single vial of blood. Cyclomics' 4th generation liquid biopsy platform, CyclomicsSeq, and GEDiCube's AI-driven biomarker panels aim to revolutionize cancer diagnosis and treatment. This collaboration is poised to disrupt the cancer diagnostics market.

Cyclomics appoints advisory board

Cyclomics has established an advisory board chaired by Joris Schuurmans, featuring experienced members from the molecular cancer diagnostics and life sciences investment sectors, to guide the company's growth and development.

Cyclomics co-founder Dr. Jeroen de Ridder publishes paper in Nature

Jeroen de Ridder's research group, co-founders of Cyclomics and inventors of CyclomicsSeq technology, has published a paper in Nature demonstrating the use of Oxford Nanopore sequencing for real-time classification of pediatric brain tumors via methylation hallmarks. This method enables rapid tumor diagnosis, essential for surgical decisions.

The Dutch Cancer Foundation (KWF) granted 1.25M to OralScreen to tackle the diagnostics challenges of oral-cavity cancers

Cyclomics is collaborating with KWF, NWO, and Amsterdam UMC in the OralScreen consortium, led by Dr. J.B. Poell from VUMC, to revolutionize early detection of oral cavity cancers. The consortium aims to use non-invasive methods like mouthwashes and swabs to identify early DNA mutations, improving early diagnosis and decision-making for medical professionals.

Oxford Nanopore Technologies and Cyclomics begin developer testing on non-invasive method for accurate and fast detection of molecules associated with cancer

Oxford Nanopore Technologies and Cyclomics announced a new 'liquid biopsy' research workflow using nanopore sequencing for ultra-sensitive detection of circulating tumor DNA (ctDNA) in blood. The CyclomicsSeq technology enables highly accurate sequencing of individual cancer DNA molecules, facilitating rapid and low-cost cancer detection from a blood draw, and is being trialed with select users for broader clinical applications.

Cyclomics announces completion of seed financing round

Cyclomics has completed a financing round with private investors to accelerate the development of innovative cancer genetic testing technologies. The new funding will allow Cyclomics to expand beyond its core CyclomicsSeq technology, enhancing its capacity to develop faster and cost-efficient methods for cancer detection, with the aim of becoming a major player in the field.

Appointment of Rodrigo Meneses as Bioinformatics Scientist at Cyclomics

Cyclomics has expanded its bioinformatics team by adding Rodrigo Meneses, who holds a Master's degree in Bioinformatics from Ghent University and a biological degree from the University of Aveiro. His medical experience will enhance Cyclomics' analytical software and capabilities.

Appointment of Rita Ferreira as Molecular Biology Scientist at Cyclomics

Cyclomics welcomes its newest team member, Rita Ferreira, who holds a PhD in Medical Microbiology from the University of Groningen. Rita's expertise in cell and molecular biology will enhance the design and implementation of novel molecular assays and laboratory development at Cyclomics.

Cyclomics finalizes Oncode clinical proof-of-concept project

CyclomicsSeq technology was utilized in a Clinical Proof-of-Concept (CPoC) project funded by the Oncode Institute, monitoring patients with advanced head and neck cancer to distinguish between treatment responders and non-responders. The project provided promising results that pave the way for validating CyclomicsSeq in clinical practice.

Cyclomics presents technology at Oxford Nanopore Cancer Research Symposium

Cyclomics' CSO Wigard Kloosterman presented the CyclomicsSeq technology at the online Cancer Research Symposium by Oxford Nanopore Technologies. The presentation detailed the use of CyclomicsSeq for monitoring treatment response and recurrence, with potential for routine cancer monitoring and pre-symptomatic screening.

Cyclomics announces publication on CyclomicsSeq technology

Cyclomics has published a study in Genomic Medicine showcasing their CyclomicsSeq technology, optimized for detecting cancer mutations in circulating tumor DNA through a novel sequencing approach. This technology offers high sensitivity and broad mutation coverage, potentially revolutionizing cancer detection using liquid biopsies and Oxford Nanopore sequencing.

Appointment of Dàmi Rebergen as bioinformatician at Cyclomics

Cyclomics has appointed Dàmi Rebergen to enhance their bioinformatics capabilities. Dami will play a crucial role in developing a user-friendly bioinformatic analysis and reporting pipeline for CyclomicsSeq.

CyclomicsSeq manuscript available as preprint

We are excited to announce the publication of our preprint manuscript on CyclomicsSeq, a technology for high-accuracy sequencing of short circulating tumor DNA molecules, on biorxiv.org. CyclomicsSeq, compatible with any long-read DNA sequencer, significantly enhances Oxford Nanopore sequencing quality by 60-fold, enabling the detection of rare cancer mutations, including those in the TP53 gene.

Cyclomics and University Medical Center Utrecht sign collaboration agreement

Following the licensing of liquid biopsy technology from the University Medical Center Utrecht, Cyclomics and UMC Utrecht have entered a long-term collaboration to advance the CyclomicsSeq platform technology for cancer diagnostics. This partnership allows Cyclomics to utilize UMC Utrecht's clinical oncology expertise and infrastructure, accelerating the development and clinical evaluation of CyclomicsSeq.

Cyclomics highlighted on Nature Methods

Cyclomics and its innovative CyclomicsSeq technology were featured in Nature Methods, highlighting the use of Oxford Nanopore sequencing for real-time, bedside cancer diagnostics. The article emphasizes CyclomicsSeq's rapid and cost-effective assay for detecting cancer mutations, showcasing its significant potential in improving patient outcomes.

Cyclomics highlighted on GenomeWeb

Cyclomics founders Alessio Marcozzi and Jeroen de Ridder were featured in GenomeWeb, discussing CyclomicsSeq technology for detecting cancer mutations in circulating tumor DNA. The article details the company's structure, ongoing clinical trials for TP53 mutations in head and neck cancer, and future plans for clinical validation and commercialization of their affordable, point-of-care diagnostic platform.

Cyclomics presents at LC 2019

At the annual London Calling conference, Cyclomics CEO Jeroen de Ridder presented breakthrough results from their CyclomicsSeq platform, demonstrating highly sensitive detection of TP53 mutations in head-and-neck cancer patients' blood, with further comparative results expected by the end of 2019.

Cyclomics gets the SME Instrument grant

Cyclomics received a €50,000 grant from the European Commission's SME Instrument phase 1 program to advance their CyclomicsSeq TP53 ctDNA mutation detection assay, with a focus on market needs and IP positioning, as part of their commercialization strategy.

Funds for clinical testing in collaboration with UMCU & NKI

Cyclomics, in collaboration with the University Medical Center Utrecht and the Netherlands Cancer Institute, will use their highly accurate CyclomicsSeq technology to monitor TP53 mutations in circulating tumor DNA for recurrence detection and treatment response in advanced stage head and neck cancer patients, supported by a grant from the Oncode Institute.

Cyclomics obtains the Take-Off grant

Cyclomics and the University Medical Center Utrecht received €50,000 to develop and evaluate their mutation detection technology, focusing on DNA concatemerization and advanced bioinformatics, with plans to test its sensitivity in liquid biopsies and prepare for clinical trials.

Cyclomics wins the Venture Challenge

Cyclomics won the Health Holland Venture Challenge fall 2017, earning €25,000 for their detailed business plan and pitch on their proprietary DNA concatemerization technology for cancer liquid biopsy genetic testing, developed by founders Alessio Marcozzi, Jeroen de Ridder, and Wigard Kloosterman, following extensive coaching and preparation.